Physiological Effects and Subjective Tolerability of Prone Positioning in COVID-19 and Healthy Hypoxic Challenge
Overview
Authors
Affiliations
Background: Prone positioning has a beneficial role in coronavirus disease 2019 (COVID-19) patients receiving ventilation but lacks evidence in awake non-ventilated patients, with most studies being retrospective, lacking control populations and information on subjective tolerability.
Methods: We conducted a prospective, single-centre study of prone positioning in awake non-ventilated patients with COVID-19 and non-COVID-19 pneumonia. The primary outcome was change in peripheral oxygenation in prone supine position. Secondary outcomes assessed effects on end-tidal CO, respiratory rate, heart rate and subjective symptoms. We also recruited healthy volunteers to undergo proning during hypoxic challenge.
Results: 238 hospitalised patients with pneumonia were screened; 55 were eligible with 25 COVID-19 patients and three non-COVID-19 patients agreeing to undergo proning - the latter insufficient for further analysis. 10 healthy control volunteers underwent hypoxic challenge. Patients with COVID-19 had a median age of 64 years (interquartile range 53-75). Proning led to an increase in oxygen saturation measured by pulse oximetry (pO) compared to supine position (difference +1.62%; p=0.003) and occurred within 10 min of proning. There were no effects on end-tidal CO, respiratory rate or heart rate. There was an increase in subjective discomfort (p0.003), with no difference in breathlessness. Among healthy controls undergoing hypoxic challenge, proning did not lead to a change in SpO or subjective symptom scores.
Conclusion: Identification of suitable patients with COVID-19 requiring oxygen supplementation from general ward environments for awake proning is challenging. Prone positioning leads to a small increase in pO within 10 min of proning though is associated with increased discomfort.
Awake prone positioning effectiveness in moderate to severe COVID-19 a randomized controlled trial.
Phong N, Duc D, Hai H, Nguyen N, Khoa L, Khanh L Wellcome Open Res. 2024; 9:543.
PMID: 39654551 PMC: 11626102. DOI: 10.12688/wellcomeopenres.22792.2.
Zhu L, Ni Z, Zhang Y, Zhan Y, Lan M, Zhao R BMC Pulm Med. 2023; 23(1):267.
PMID: 37468848 PMC: 10357605. DOI: 10.1186/s12890-023-02561-x.